Roger  Jeffs net worth and biography

Roger Jeffs Biography and Net Worth

Director of Axsome Therapeutics

Dr. Jeffs has been a member of our board of directors since December 2014.

Dr. Jeffs currently serves on the Board of Albireo Pharma (ALBO) and is the Vice-Chairman and co-founder of Kryia Therapeutics, a company focused on accelerating the development of innovative gene therapy programs for prevalent diseases. In addition, Dr. Jeffs served on the Board of Directors of United Therapeutics from 2001-2016, Dova Pharmaceuticals (DOVA) from 2017-2019, Sangamo Therapeutics from 2017-2019, and Axovant Gene Therapies (AXGT) from 2017-2019. Dr. Jeffs retired as President & co-CEO from United Therapeutics Corporation in 2016 after an 18-year tenure.

Dr. Jeffs joined United Therapeutics Corporation during its start-up phase in 1998 as Director of Research, Development, and Medical and served as its President and Chief Operating Officer from 2001 to 2014, and President & co-CEO from 2015-2016. While at United Therapeutics, Dr. Jeffs helped lead the IPO, oversaw the clinical development and regulatory approval of 6 products for rare diseases, and managed the commercial effort that led to a >20% CAGR and $1.5B annual revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in “recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children”. Dr. Jeffs previously held positions at Amgen, Inc. and Burroughs Wellcome Co where he held roles in clinical development.

Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.

What is Roger Jeffs' net worth?

The estimated net worth of Roger Jeffs is at least $62.20 million as of April 12th, 2024. Dr. Jeffs owns 826,985 shares of Axsome Therapeutics stock worth more than $62,197,542 as of May 30th. This net worth evaluation does not reflect any other assets that Dr. Jeffs may own. Learn More about Roger Jeffs' net worth.

How do I contact Roger Jeffs?

The corporate mailing address for Dr. Jeffs and other Axsome Therapeutics executives is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. Axsome Therapeutics can also be reached via phone at (212) 332-3241. Learn More on Roger Jeffs' contact information.

Has Roger Jeffs been buying or selling shares of Axsome Therapeutics?

Roger Jeffs has not been actively trading shares of Axsome Therapeutics during the last quarter. Most recently, Roger Jeffs sold 29,976 shares of the business's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a transaction totalling $2,089,327.20. Following the completion of the sale, the director now directly owns 120,756 shares of the company's stock, valued at $8,416,693.20. Learn More on Roger Jeffs' trading history.

Who are Axsome Therapeutics' active insiders?

Axsome Therapeutics' insider roster includes Mark Coleman (Director), Roger Jeffs (Director), Nick Pizzie (CFO), and Mark Saad (Director). Learn More on Axsome Therapeutics' active insiders.

Are insiders buying or selling shares of Axsome Therapeutics?

During the last twelve months, insiders at the sold shares 5 times. They sold a total of 78,813 shares worth more than $5,805,082.51. The most recent insider tranaction occured on May, 29th when COO Mark L Jacobson sold 7,910 shares worth more than $587,792.10. Insiders at Axsome Therapeutics own 22.4% of the company. Learn More about insider trades at Axsome Therapeutics.

Information on this page was last updated on 5/29/2024.

Roger Jeffs Insider Trading History at Axsome Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2024Sell29,976$69.70$2,089,327.20120,756View SEC Filing Icon  
11/19/2021Buy3,950$37.30$147,335.00View SEC Filing Icon  
See Full Table

Roger Jeffs Buying and Selling Activity at Axsome Therapeutics

This chart shows Roger Jeffs's buying and selling at Axsome Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Axsome Therapeutics Company Overview

Axsome Therapeutics logo
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Read More

Today's Range

Now: $75.21
Low: $73.17
High: $75.95

50 Day Range

MA: $74.42
Low: $65.72
High: $80.86

2 Week Range

Now: $75.21
Low: $55.02
High: $98.40


636,266 shs

Average Volume

684,107 shs

Market Capitalization

$3.57 billion

P/E Ratio


Dividend Yield